FATE vs. TNYA, AGEN, OMGA, VYGR, AMAM, AUTL, ITOS, AURA, TARS, and MGTX
Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Tenaya Therapeutics (TNYA), Agenus (AGEN), Omega Therapeutics (OMGA), Voyager Therapeutics (VYGR), Ambrx Biopharma (AMAM), Autolus Therapeutics (AUTL), iTeos Therapeutics (ITOS), Aura Biosciences (AURA), Tarsus Pharmaceuticals (TARS), and MeiraGTx (MGTX). These companies are all part of the "biological products, except diagnostic" industry.
Fate Therapeutics vs.
Fate Therapeutics (NASDAQ:FATE) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Fate Therapeutics presently has a consensus price target of $16.24, suggesting a potential upside of 216.48%. Tenaya Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 168.24%. Given Fate Therapeutics' higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than Tenaya Therapeutics.
Fate Therapeutics received 464 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. Likewise, 70.94% of users gave Fate Therapeutics an outperform vote while only 60.00% of users gave Tenaya Therapeutics an outperform vote.
Tenaya Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fate Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Tenaya Therapeutics. Fate Therapeutics' average media sentiment score of 0.69 beat Tenaya Therapeutics' score of 0.43 indicating that Fate Therapeutics is being referred to more favorably in the media.
Fate Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.
Tenaya Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -171.64%. Fate Therapeutics' return on equity of -45.62% beat Tenaya Therapeutics' return on equity.
Summary
Fate Therapeutics beats Tenaya Therapeutics on 10 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fate Therapeutics Competitors List
Related Companies and Tools